Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today ...

Q4 2024 Earnings Call Transcript March 10, 2025 Fennec Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is ...

Jaggery sold in Bengaluru markets has been found adulterated with harmful chemicals like washing soda, chalk powder, and ...

Over-Year, and Generated PEDMARK ® Q4 2024 Net Product Sales of $7.9 Million ~ ~ Delivered Q4 2024 EBITDA Loss of $0.6 Million and Company Has $26.6 Million in Cash, Cash Equivalents and Short-Term ...

Montpellier, France Monday, March 10, 2025, 15:00 Hrs [IST] ...

Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of SENS-401 for the Prevention of Cisplatin-Induced Ototoxicity ...

Introduction: Robust clinically relevant epidemiological and audiological data are needed to prepare for future clinical trials aiming at preventing cisplatin-induced ototoxicity in this suffering ...

2005). Ototoxicity is well-established toxicity associated with therapeutic agents for causing cochlear impairment and the prevalence of ototoxicity-induced hearing loss ranges from 4 to 90% in ...

The company is currently conducting a Phase II proof of concept study of SENS-401 to preserve residual hearing in patients with cisplatin-induced ototoxicity (CIO). In June 2023, Sensorion reported ...

—ARIKAYCE ® (amikacin liposome inhalation suspension) Total Revenue of $104.4 Million for Fourth-Quarter and $363.7 Million for Full-Year 2024, Reflecting 19% Annual Growth and Exceeding the ...